Effective mobilisation of peripheral blood progenitor cells with 'Dexa-BEAM' and G-CSF: timing of harvesting and composition of the leukapheresis product.

The mini-BEAM regimen (BCNU, etoposide, cytarabine, melphalan) and its modification 'Dexa-BEAM' are effective salvage protocols for relapsed Hodgkin's disease and non-Hodgkin's lymphoma. Since many patients with relapsed lymphoma are eligible for high-dose chemotherapy with autol...

Descripción completa

Detalles Bibliográficos
Autores principales: Dreger, P., Marquardt, P., Haferlach, T., Jacobs, S., Mülverstedt, T., Eckstein, V., Suttorp, M., Löffler, H., Müller-Ruchholtz, W., Schmitz, N.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1993
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968738/
https://www.ncbi.nlm.nih.gov/pubmed/7692921
_version_ 1782134805962424320
author Dreger, P.
Marquardt, P.
Haferlach, T.
Jacobs, S.
Mülverstedt, T.
Eckstein, V.
Suttorp, M.
Löffler, H.
Müller-Ruchholtz, W.
Schmitz, N.
author_facet Dreger, P.
Marquardt, P.
Haferlach, T.
Jacobs, S.
Mülverstedt, T.
Eckstein, V.
Suttorp, M.
Löffler, H.
Müller-Ruchholtz, W.
Schmitz, N.
author_sort Dreger, P.
collection PubMed
description The mini-BEAM regimen (BCNU, etoposide, cytarabine, melphalan) and its modification 'Dexa-BEAM' are effective salvage protocols for relapsed Hodgkin's disease and non-Hodgkin's lymphoma. Since many patients with relapsed lymphoma are eligible for high-dose chemotherapy with autologous stem cell rescue, we were interested in the suitability of these second line regimens for mobilising peripheral blood progenitor cells (PBPC). The kinetics of PBPC were studied in 15 patients treated with Dexa-BEAM and granulocyte colony-stimulating factor (G-CSF). Leukocytes started to rise from < 0.5 nL-1 on day 18 (16-22) after Dexa-BEAM, and exceeded 10 nL-1 on day 20 (18-28). Peripheral blood CFU-GM peaked on day 21 (19-28) and declined slowly thereafter; the median leukocyte count was 18.7 nL-1 (12.2-60) on the day of CFU-GM-peak. The maximum number of CFU-GM circulating in peripheral blood was inversely correlated to the duration of leukopenia after Dexa-BEAM. Measurement of CD34+ cells with the monoclonal antibody 8G12-PE (HPCA-2) predicted the number of CFU-GM precisely in both peripheral blood and leukapheresis products (r = 0.90-0.95). Two to six leukapheresis procedures yielded 6.39 x 10(8) mononuclear cells kg-1 (1.82-13.49) containing 44.4 x 10(4) CFU-GM kg-1 (2.2-213.8). Immunophenotypical analysis revealed that the percentage of CD19+ B cells was very low in all collection products (less than 1%). Nine patients were autografted with PBPC (15.4-213.8 x 10(4) CFU-GM kg-1) after myeloablative chemotherapy and experienced rapid and sustained engraftment (Platelets > 50 nL-1 on day +13 [9-22]). We conclude that PBPC can be mobilised effectively by Dexa-BEAM plus G-CSF. An adequate timing of PBPC collection (when the leukocyte count has exceeded 10 nL-1) and evaluation of the progenitor content of the leukapheresis products with 8G12-PE will allow to minimise the number of leukaphereses.
format Text
id pubmed-1968738
institution National Center for Biotechnology Information
language English
publishDate 1993
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-19687382009-09-10 Effective mobilisation of peripheral blood progenitor cells with 'Dexa-BEAM' and G-CSF: timing of harvesting and composition of the leukapheresis product. Dreger, P. Marquardt, P. Haferlach, T. Jacobs, S. Mülverstedt, T. Eckstein, V. Suttorp, M. Löffler, H. Müller-Ruchholtz, W. Schmitz, N. Br J Cancer Research Article The mini-BEAM regimen (BCNU, etoposide, cytarabine, melphalan) and its modification 'Dexa-BEAM' are effective salvage protocols for relapsed Hodgkin's disease and non-Hodgkin's lymphoma. Since many patients with relapsed lymphoma are eligible for high-dose chemotherapy with autologous stem cell rescue, we were interested in the suitability of these second line regimens for mobilising peripheral blood progenitor cells (PBPC). The kinetics of PBPC were studied in 15 patients treated with Dexa-BEAM and granulocyte colony-stimulating factor (G-CSF). Leukocytes started to rise from < 0.5 nL-1 on day 18 (16-22) after Dexa-BEAM, and exceeded 10 nL-1 on day 20 (18-28). Peripheral blood CFU-GM peaked on day 21 (19-28) and declined slowly thereafter; the median leukocyte count was 18.7 nL-1 (12.2-60) on the day of CFU-GM-peak. The maximum number of CFU-GM circulating in peripheral blood was inversely correlated to the duration of leukopenia after Dexa-BEAM. Measurement of CD34+ cells with the monoclonal antibody 8G12-PE (HPCA-2) predicted the number of CFU-GM precisely in both peripheral blood and leukapheresis products (r = 0.90-0.95). Two to six leukapheresis procedures yielded 6.39 x 10(8) mononuclear cells kg-1 (1.82-13.49) containing 44.4 x 10(4) CFU-GM kg-1 (2.2-213.8). Immunophenotypical analysis revealed that the percentage of CD19+ B cells was very low in all collection products (less than 1%). Nine patients were autografted with PBPC (15.4-213.8 x 10(4) CFU-GM kg-1) after myeloablative chemotherapy and experienced rapid and sustained engraftment (Platelets > 50 nL-1 on day +13 [9-22]). We conclude that PBPC can be mobilised effectively by Dexa-BEAM plus G-CSF. An adequate timing of PBPC collection (when the leukocyte count has exceeded 10 nL-1) and evaluation of the progenitor content of the leukapheresis products with 8G12-PE will allow to minimise the number of leukaphereses. Nature Publishing Group 1993-11 /pmc/articles/PMC1968738/ /pubmed/7692921 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Dreger, P.
Marquardt, P.
Haferlach, T.
Jacobs, S.
Mülverstedt, T.
Eckstein, V.
Suttorp, M.
Löffler, H.
Müller-Ruchholtz, W.
Schmitz, N.
Effective mobilisation of peripheral blood progenitor cells with 'Dexa-BEAM' and G-CSF: timing of harvesting and composition of the leukapheresis product.
title Effective mobilisation of peripheral blood progenitor cells with 'Dexa-BEAM' and G-CSF: timing of harvesting and composition of the leukapheresis product.
title_full Effective mobilisation of peripheral blood progenitor cells with 'Dexa-BEAM' and G-CSF: timing of harvesting and composition of the leukapheresis product.
title_fullStr Effective mobilisation of peripheral blood progenitor cells with 'Dexa-BEAM' and G-CSF: timing of harvesting and composition of the leukapheresis product.
title_full_unstemmed Effective mobilisation of peripheral blood progenitor cells with 'Dexa-BEAM' and G-CSF: timing of harvesting and composition of the leukapheresis product.
title_short Effective mobilisation of peripheral blood progenitor cells with 'Dexa-BEAM' and G-CSF: timing of harvesting and composition of the leukapheresis product.
title_sort effective mobilisation of peripheral blood progenitor cells with 'dexa-beam' and g-csf: timing of harvesting and composition of the leukapheresis product.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968738/
https://www.ncbi.nlm.nih.gov/pubmed/7692921
work_keys_str_mv AT dregerp effectivemobilisationofperipheralbloodprogenitorcellswithdexabeamandgcsftimingofharvestingandcompositionoftheleukapheresisproduct
AT marquardtp effectivemobilisationofperipheralbloodprogenitorcellswithdexabeamandgcsftimingofharvestingandcompositionoftheleukapheresisproduct
AT haferlacht effectivemobilisationofperipheralbloodprogenitorcellswithdexabeamandgcsftimingofharvestingandcompositionoftheleukapheresisproduct
AT jacobss effectivemobilisationofperipheralbloodprogenitorcellswithdexabeamandgcsftimingofharvestingandcompositionoftheleukapheresisproduct
AT mulverstedtt effectivemobilisationofperipheralbloodprogenitorcellswithdexabeamandgcsftimingofharvestingandcompositionoftheleukapheresisproduct
AT ecksteinv effectivemobilisationofperipheralbloodprogenitorcellswithdexabeamandgcsftimingofharvestingandcompositionoftheleukapheresisproduct
AT suttorpm effectivemobilisationofperipheralbloodprogenitorcellswithdexabeamandgcsftimingofharvestingandcompositionoftheleukapheresisproduct
AT lofflerh effectivemobilisationofperipheralbloodprogenitorcellswithdexabeamandgcsftimingofharvestingandcompositionoftheleukapheresisproduct
AT mullerruchholtzw effectivemobilisationofperipheralbloodprogenitorcellswithdexabeamandgcsftimingofharvestingandcompositionoftheleukapheresisproduct
AT schmitzn effectivemobilisationofperipheralbloodprogenitorcellswithdexabeamandgcsftimingofharvestingandcompositionoftheleukapheresisproduct

Ejemplares similares